Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Oldesloe – page 13

1 417 clinical trials in Bad Oldesloe, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Oldesloe at a glance
1 417
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 417 trials in Bad Oldesloe

Open in trial search

HIV infection

Recruiting

Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abacavir
  • Sponsor:Gilead Sciences Inc.

HIV infection

Recruiting

Switching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Gilead Sciences Inc.

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Healthcare KGaA

A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Etentamig
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Recruiting

Study of BMS-986504 alone or in drug combination in adults with advanced or metastatic solid tumors with MTAP deletion

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-79635322
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Oldesloe

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on anticoagulation therapy in patients with irregular heartbeat who have undergone coronary stent placement. The research evaluates new approaches to prevent blood clot formation while maintaining patient safety.

  • Atrial Fibrillation Management
  • Post-PCI Treatment Strategies
  • Bleeding Risk Assessment

These trials aim to optimize antithrombotic treatment regimens following coronary interventions.

02 Coronary Interventions

Advanced research investigating treatment strategies for patients with ST-Elevated Myocardial Infarction, comparing different approaches to antiplatelet therapy and revascularization techniques.

  • Prasugrel-based Therapy
  • OCT-guided Procedures
  • Stent Optimization

The studies focus on improving outcomes in heart attack patients through innovative imaging and medication protocols.

03 Interventional Cardiology

Comprehensive evaluation of dual antiplatelet therapy protocols and their optimization in patients undergoing coronary interventions, with special attention to timing and duration of treatment.

  • Revascularization Techniques
  • Medication Protocols
  • Patient Safety Outcomes

These studies aim to establish more effective and safer treatment strategies for cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.